Epilepsy Case Review & Advanced Treatment Pathway Coordination

• Clear timeline: age at first event, diagnosis date, seizure frequency, pattern over time, triggers, injuries, emergency visits, and hospitalizations.
• Seizure diary, including daytime versus nocturnal events, clusters, aura, loss of awareness, duration, recovery time, and postictal symptoms.
• Eyewitness descriptions from family, carers, teachers, or colleagues.
• Smartphone videos of typical events if available and safe to obtain.
• Description of how events start, how they spread, which side of the body is involved, whether consciousness is preserved or impaired, and whether seizures become bilateral tonic-clonic.
• Information about driving, work, school, pregnancy planning, living alone, sleep safety, and other practical safety concerns.

• Current antiseizure medications: name, dose, timing, formulation, adherence, benefits, and side effects.
• Previous antiseizure medications: dose range, duration, reason stopped, seizure response, adverse effects, and whether the trial was considered adequate.
• Medication allergies, intolerances, interactions, contraception/pregnancy considerations, psychiatric side effects, cognitive effects, fatigue, dizziness, or balance problems.
• Rescue medication plan, emergency medication history, and any repeated use of benzodiazepines or emergency treatment.
• Prior dietary therapy, VNS, DBS, RNS-type device, epilepsy surgery, ablation, or invasive monitoring records if applicable.

• Routine EEG reports and, where possible, original EEG files or representative pages.
• Sleep-deprived, ambulatory, or prolonged EEG reports.
• Video-EEG telemetry reports, including captured events, ictal onset, interictal findings, medication taper details, and final interpretation.
• SEEG, subdural grid/strip, or other invasive monitoring reports if already performed.
• Any prior epilepsy conference or MDT conclusions based on EEG/VEEG data.

• Epilepsy-protocol brain MRI, preferably as DICOM files, not only screenshots or PDF reports.
• Radiology reports and, if available, specialist neuroradiology review.
• Earlier MRI/CT studies for comparison, especially if the first MRI was done many years ago or not with epilepsy protocol.
• PET, ictal/interictal SPECT, MEG, fMRI, tractography, language/memory lateralization, or other functional imaging when available.
• Imaging related to suspected lesions such as hippocampal sclerosis, focal cortical dysplasia, low-grade epilepsy-associated tumor, vascular malformation, hypothalamic hamartoma, tuberous sclerosis, old trauma, stroke, or infection.

• Neuropsychology reports, memory/language assessment, school or developmental reports, cognitive baseline, and learning profile.
• Psychiatry or psychology history, including depression, anxiety, trauma, psychosis, non-epileptic events, and treatment history.
• Pediatric developmental history, birth history, febrile seizures, developmental regression, autism/learning disability, and genetic/metabolic testing if relevant.
• Genetic testing, metabolic testing, autoimmune encephalitis antibody testing, infection history, oncology history, stroke/trauma history, or other possible causes.
• Current medical conditions, pregnancy status, implanted devices, surgical history, and anesthesia or travel risks.

Not every seizure-like event is epilepsy. Specialist review may need to distinguish epileptic seizures from syncope, cardiac events, sleep disorders, metabolic events, migraine, movement disorders, panic attacks, psychogenic non-epileptic seizures, or mixed presentations. A detailed history, witness accounts, videos, examination, ECG, EEG, and imaging can all be relevant.

Treatment choices depend on whether seizures are focal, generalized, unknown whether focal or generalized, or part of a defined epilepsy syndrome. Focal epilepsy may require localization of a seizure network. Generalized or multifocal epilepsies may require a different medication, genetic, dietary, or neuromodulation pathway. Misclassification can lead to ineffective or inappropriate treatment.

Drug-resistant epilepsy is not simply “difficult epilepsy.” It usually means that seizures persist despite adequate trials of two tolerated, appropriately chosen and used antiseizure medication schedules. Before labeling a case drug resistant, specialists often review whether the medication was appropriate for the seizure type, whether dosing and adherence were adequate, whether side effects limited treatment, and whether the diagnosis is correct.

If MRI shows a lesion associated with focal epilepsy, the pathway may involve epilepsy-protocol MRI review, VEEG correlation, neuroradiology, neuropsychology, and epilepsy surgery discussion. Relevant lesions can include hippocampal sclerosis, focal cortical dysplasia, epilepsy-associated low-grade tumors, vascular malformations, hypothalamic hamartoma, tuberous sclerosis-related lesions, or post-traumatic/post-infectious scars. A lesion alone does not automatically mean surgery is appropriate; symptoms, EEG, imaging and functional risk must align.

A normal MRI does not necessarily end the epilepsy surgery conversation. Some MRI-negative cases may still need tertiary epilepsy review, repeat MRI with epilepsy protocol, expert neuroradiology review, PET, SPECT, MEG, neuropsychology, or invasive monitoring such as SEEG. The key question is whether a seizure network can be localized well enough and treated safely.

Temporal lobe epilepsy, extratemporal epilepsy, insular epilepsy, frontal lobe epilepsy and multilobar cases have different workups and risk profiles. If the suspected seizure onset zone is near language, memory, motor, sensory, visual or other eloquent brain areas, additional mapping and risk-benefit discussion may be needed before surgery, ablation or invasive monitoring is considered.

When seizures are generalized, multifocal, genetic, metabolic or syndromic, resective surgery may not be the right pathway. The specialist team may instead consider medication strategy, syndrome-specific treatment, ketogenic diet in selected cases, VNS or other neuromodulation, risk-reduction planning, school/work support, and long-term follow-up.

Children with early-onset seizures, developmental regression, structural lesions, drug-resistant seizures, infantile spasms, genetic syndromes, or learning and behavioural deterioration often need faster specialist review. Pediatric epilepsy coordination also has to consider development, school, family counselling, genetic testing, anesthesia/sedation for imaging, dietary therapy, and long-term transition to adult services.

Epilepsy safety planning is part of the pathway. Uncontrolled generalized tonic-clonic or focal-to-bilateral tonic-clonic seizures, nocturnal seizures, medication non-adherence, alcohol or drug misuse, living alone, and sleeping alone without supervision may increase epilepsy-related risk. Specialist review can help frame a risk-reduction plan, but this should be handled sensitively and individually.